All In Biotech

NDA 021802 · Sandoz

Focalin Xr

Dexmethylphenidate Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

May 26, 2005

Approved uses

4

Original approval plus efficacy supplements

Registered trials

33

11 Phase 3, 3 recruiting

FAERS reports

4,283

1,583 serious, 36 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE, MISUSE, AND ADDICTION Dexmethylphenidate hydrochloride extended-release capsules has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dexmethylphenidate hydrochloride extended-release capsules, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing dexmethylphenidate hydrochloride extended-release capsules, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout dexmethylphenidate hydrochloride extended-release capsules treatment, reassess each patient’s risk of abuse, misuse,...

What it is approved for

From the label in effect Apr 30, 2026.

Dexmethylphenidate hydrochloride extended-release capsules is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies ( 14 )]. Limitations of Use The use of dexmethylphenidate hydrochloride extended-release capsules is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions ( 5.7 ), Use in Specific Populations ( 8.4 )]. Dexmethylphenidate hydrochloride extended-release capsules is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) ( 1 ). Limitations of Use The use of dexmethylphenidate hydrochloride extended-release capsules is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.7 , 8.4 ).

Mechanism: Dexmethylphenidate hydrochloride is a CNS stimulant. The mode of therapeutic action in ADHD is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

8 products under this application
  • FOCALIN XR · DEXMETHYLPHENIDATE HYDROCHLORIDE 35MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • FOCALIN XR · DEXMETHYLPHENIDATE HYDROCHLORIDE 30MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • FOCALIN XR · DEXMETHYLPHENIDATE HYDROCHLORIDE 20MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • FOCALIN XR · DEXMETHYLPHENIDATE HYDROCHLORIDE 5MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • FOCALIN XR · DEXMETHYLPHENIDATE HYDROCHLORIDE 25MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • FOCALIN XR · DEXMETHYLPHENIDATE HYDROCHLORIDE 40MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • FOCALIN XR · DEXMETHYLPHENIDATE HYDROCHLORIDE 15MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • FOCALIN XR · DEXMETHYLPHENIDATE HYDROCHLORIDE 10MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dexmethylphenidate" as an intervention, any sponsor and status, largest first.

All 33 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective769
  • nausea206
  • anxiety199
  • headache188
  • fatigue176
  • abnormal behaviour168
  • feeling abnormal167
  • decreased appetite160
  • disturbance in attention158
  • off label use150
  • insomnia147
  • aggression144

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200414
200531
200678
200782
200882
200983
201082
2011114
2012125
2013116
2014149
2015394
2016420
2017313
2018245
2019277
2020242
2021177
2022244
2023303
2024263
2025258
2026191

Recalls

1 FDA enforcement reports for this application.

  • Jun 1, 2026 · Class III · Ongoing

    Labeling: Incorrect or Missing Lot and/or Exp Date

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Focalin XR (Dexmethylphenidate HCl)

2024 spending

$1.1M

Beneficiaries

939

3,848 claims

Per beneficiary

$1,133

$7.64 per unit

View as table
YearSpending
2020$1,211,978
2021$1,234,967
2022$1,362,688
2023$1,884,658
2024$1,063,615

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 42 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.